Skip to main content
Premium Trial:

Request an Annual Quote

LetsGetChecked Closes $150M Funding Round

NEW YORK – Digital care company LetsGetChecked announced on Tuesday that it has completed a $150 million Series D financing round.

The round was led by Casdin Capital with participation from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners, Qiming Venture Partners USA, and Symphony Ventures. LetsGetChecked has raised more than $260 million to date, it said in a statement. The company closed a $71 million Series C round last May.

The company, co-headquartered in New York and Dublin, plans to use the money to launch services to provide remote care for patients with chronic conditions. It will launch expanded virtual customer consultation capabilities, including asynchronous chat and video, allowing patients to have a telehealth visit, receive follow-up care, and get prescriptions refilled or adjusted.

It also plans to expand its pharmaceutical services to include long-term care solutions for chronic issues like thyroid management. The company is acquiring a pharmacy in Jupiter, Florida, to help in the expansion, it said.

"We are seeing unprecedented demand for at-home diagnostics and care as an alternative to traditional in-person medical visits, and we are expanding our offerings to include telehealth and treatment services to further help people live longer, happier lives," Peter Foley, founder and CEO of LetsGetChecked, said in a statement.

The firm currently offers more than 100 at-home tests, including those for sexual health, cholesterol, diabetes, and COVID-19, with more on the way in 2021, and follow-up care through its telehealth and pharmacy offerings. Its molecular SARS-CoV-2 test with at-home sample collection received Emergency Use Authorization from the US Food and Drug Administration last May.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.